Australia - inglese - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ramipril, quantity: 10 mg - capsule - excipient ingredients: lactose monohydrate; titanium dioxide; gelatin; erythrosine; magnesium stearate; iron oxide black; indigo carmine; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; ethanol; shellac; sulfuric acid - ? treatment of hypertension. (data are currently not available to support the use of ramipril in renovascular hypertension).,? post mi heart failure.,? prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day.,? for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke or peripheral vascular disease.,? for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure > 160 mm hg or diastolic blood pressure > 90 mm hg (or on antihypertensive treatment); total cholesterol > 5.2 mmol/l; hdl cholesterol < 0.9 mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ramipril, quantity: 5 mg - tablet - excipient ingredients: microcrystalline cellulose; sodium stearylfumarate; hypromellose; pregelatinised maize starch; iron oxide yellow - treatment of hypertension. data are currently not available to support the use of ramipril in renovascular hypertension.,post mi heart failure,prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day.,for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke, or peripheral vascular disease.,for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160mmhg or diastolic blood pressure >90mmhg (or on antihypertensive treatment); total cholesterol >5.2mmol/l; hdl cholesterol <0.9mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ramipril, quantity: 10 mg - tablet - excipient ingredients: sodium stearylfumarate; pregelatinised maize starch; iron oxide yellow; microcrystalline cellulose; hypromellose - treatment of hypertension. data are currently not available to support the use of ramipril in renovascular hypertension.,post mi heart failure,prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day.,for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke, or peripheral vascular disease.,for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160mmhg or diastolic blood pressure >90mmhg (or on antihypertensive treatment); total cholesterol >5.2mmol/l; hdl cholesterol <0.9mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ramipril, quantity: 2.5 mg - tablet - excipient ingredients: hypromellose; microcrystalline cellulose; pregelatinised maize starch; sodium stearylfumarate; iron oxide red - treatment of hypertension. data are currently not available to support the use of ramipril in renovascular hypertension.,post mi heart failure,prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day.,for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke, or peripheral vascular disease.,for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160mmhg or diastolic blood pressure >90mmhg (or on antihypertensive treatment); total cholesterol >5.2mmol/l; hdl cholesterol <0.9mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

Malta - inglese - Medicines Authority

aurobindo pharma (malta) limited vault 14, level 2, valletta waterfront, floriana frn 1913, malta - hydrochlorothiazide, losartan potassium - film-coated tablet - hydrochlorothiazide 12.5 mg losartan potassium 50 mg - agents acting on the renin-angiotensin system

Malta - inglese - Medicines Authority

aurobindo pharma (malta) limited vault 14, level 2, valletta waterfront, floriana frn 1913, malta - hydrochlorothiazide, losartan potassium - film-coated tablet - hydrochlorothiazide 12.5 mg losartan potassium 100 mg - agents acting on the renin-angiotensin system

Malta - inglese - Medicines Authority

aurobindo pharma (malta) limited vault 14, level 2, valletta waterfront, floriana frn 1913, malta - hydrochlorothiazide, losartan potassium - film-coated tablet - hydrochlorothiazide 25 mg losartan potassium 100 mg - agents acting on the renin-angiotensin system

Malta - inglese - Medicines Authority

aurobindo pharma (malta) limited vault 14, level 2, valletta waterfront, floriana frn 1913, malta - ramipril - tablet - ramipril 5 mg - agents acting on the renin-angiotensin system

Malta - inglese - Medicines Authority

aurobindo pharma (malta) limited vault 14, level 2, valletta waterfront, floriana frn 1913, malta - ramipril - tablet - ramipril 10 mg - agents acting on the renin-angiotensin system

Stati Uniti - inglese - NLM (National Library of Medicine)

carilion materials management - ramipril (unii: l35jn3i7sj) (ramiprilat - unii:6n5u4qfc3g) - ramipril 1.25 mg - ramipril is indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms